San Diego, CA -- (ReleaseWire) -- 07/15/2014 -- An investigation on behalf of current long-term investors in shares CTI BioPharma Corp (NASDAQ:CTIC) shares was announced over potential breaches of fiduciary duties by certain officers and directors at CTI BioPharma, formerly Cell Therapeutics.
Investors who purchased shares of CTI BioPharma Corp (NASDAQ:CTIC) and currently hold any of those NASDAQ:CTIC shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain CTI BioPharma officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
CTI BioPharma Corp reported that its annual Total Revenue rose to $34.68 million in 2013 and that its Net Loss of $101.37 million in 2012 declined to a Net Loss of $42.74 million in 2013. Shares of CTI BioPharma Corp (NASDAQ:CTIC) grew from $1.03 per share in July 2013 to as high as $4.00 per share in January 2014. Since then NASDAQ:CTIC shares declined to $2.68 per share on July 11, 2014.
On July 11, 2014, NASDAQ:CTIC shares closed at $2.69 per share.
Those who purchased shares of CTI BioPharma Corp (NASDAQ:CTIC), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego